153 related articles for article (PubMed ID: 9553844)
1. Increased rate of factor V Leiden mutation in patients with cerebral venous thrombosis.
Weih M; Vetter B; Ziemer S; Mehraein S; Valdueza JM; Koscielny J; Kulozik AE; Einhäupl KM
J Neurol; 1998 Mar; 245(3):149-52. PubMed ID: 9553844
[TBL] [Abstract][Full Text] [Related]
2. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis.
Deschiens MA; Conard J; Horellou MH; Ameri A; Preter M; Chedru F; Samama MM; Bousser MG
Stroke; 1996 Oct; 27(10):1724-30. PubMed ID: 8841318
[TBL] [Abstract][Full Text] [Related]
3. The factor V Leiden mutation: spectrum of thrombotic events and laboratory evaluation.
Bontempo FA; Hassett AC; Faruki H; Steed DL; Webster MW; Makaroun MS
J Vasc Surg; 1997 Feb; 25(2):271-5; discussion 276. PubMed ID: 9052561
[TBL] [Abstract][Full Text] [Related]
4. Factor V gene mutation is a risk factor for cerebral venous thrombosis.
Martinelli I; Landi G; Merati G; Cella R; Tosetto A; Mannucci PM
Thromb Haemost; 1996 Mar; 75(3):393-4. PubMed ID: 8701395
[TBL] [Abstract][Full Text] [Related]
5. Normalized activated protein C ratio itself not associated with increased risk of venous thromboembolism.
Heinemann LA; Assmann A; Spannagl M; Schramm W; Dick A; Kluft C; de Maat MP
Contraception; 1998 Nov; 58(5):321-2. PubMed ID: 9883389
[TBL] [Abstract][Full Text] [Related]
6. Factor V Leiden mutation in cerebral venous thrombosis.
Zuber M; Toulon P; Marnet L; Mas JL
Stroke; 1996 Oct; 27(10):1721-3. PubMed ID: 8841317
[TBL] [Abstract][Full Text] [Related]
7. Activated-protein-C resistance in cancer patients.
Green D; Maliekel K; Sushko E; Akhtar R; Soff GA
Haemostasis; 1997; 27(3):112-8. PubMed ID: 9306127
[TBL] [Abstract][Full Text] [Related]
8. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families.
Martinelli I; Mannucci PM; De Stefano V; Taioli E; Rossi V; Crosti F; Paciaroni K; Leone G; Faioni EM
Blood; 1998 Oct; 92(7):2353-8. PubMed ID: 9746774
[TBL] [Abstract][Full Text] [Related]
9. Resistance to activated protein C (APC): mutation at Arg506 of coagulation factor V and vascular access thrombosis in haemodialysis patients.
Födinger M; Mannhalter C; Pabinger I; Koizar D; Rintelen C; Hörl WH; Sunder-Plassmann G
Nephrol Dial Transplant; 1996 Apr; 11(4):668-72. PubMed ID: 8671856
[TBL] [Abstract][Full Text] [Related]
10. Fatal cerebral venous sinus thrombosis associated with the factor V Leiden mutation and the use of oral contraceptives.
Bridey F; Wolff M; Laissy JP; Morin V; Lefebvre M; de Prost D
Thromb Haemost; 1995 Nov; 74(5):1382. PubMed ID: 8607129
[No Abstract] [Full Text] [Related]
11. Probability of recurrence of thrombosis in patients with and without factor V Leiden.
Rintelen C; Pabinger I; Knöbl P; Lechner K; Mannhalter C
Thromb Haemost; 1996 Feb; 75(2):229-32. PubMed ID: 8815565
[TBL] [Abstract][Full Text] [Related]
12. Cerebral venous thrombosis and activated protein C resistance.
Dulli DA; Luzzio CC; Williams EC; Schutta HS
Stroke; 1996 Oct; 27(10):1731-3. PubMed ID: 8841319
[TBL] [Abstract][Full Text] [Related]
13. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives?
Schambeck CM; Schwender S; Haubitz I; Geisen UE; Grossmann RE; Keller F
Thromb Haemost; 1997 Dec; 78(6):1480-3. PubMed ID: 9423798
[TBL] [Abstract][Full Text] [Related]
14. Low thrombosis rate seen in blood donors and their relatives with inherited deficiencies of antithrombin and protein C: correlation with type of defect, family history, and absence of the factor V Leiden mutation.
McColl M; Tait RC; Walker ID; Perry DJ; McCall F; Conkie JA
Blood Coagul Fibrinolysis; 1996 Oct; 7(7):689-94. PubMed ID: 8958391
[TBL] [Abstract][Full Text] [Related]
15. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
16. [Activated protein C resistance and venous thrombophilia: molecular genetic prevalence study in the German population].
Ehrenforth S; Klinke S; von Depka Prondzinski M; Kreuz W; Ganser A; Scharrer I
Dtsch Med Wochenschr; 1999 Jun; 124(25-26):783-7. PubMed ID: 10414227
[TBL] [Abstract][Full Text] [Related]
17. Influence of factor VIII/von Willebrand complex on the activated protein C-resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation.
De Mitrio V; Marino R; Scaraggi FA; Di Bari L; Giannoccaro F; Petronelli M; Ranieri P; Tannoia N; Schiraldi O
Blood Coagul Fibrinolysis; 1999 Oct; 10(7):409-16. PubMed ID: 10695766
[TBL] [Abstract][Full Text] [Related]
18. High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives.
Martinelli I; Sacchi E; Landi G; Taioli E; Duca F; Mannucci PM
N Engl J Med; 1998 Jun; 338(25):1793-7. PubMed ID: 9632445
[TBL] [Abstract][Full Text] [Related]
19. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective.
Price DT; Ridker PM
Ann Intern Med; 1997 Nov; 127(10):895-903. PubMed ID: 9382368
[TBL] [Abstract][Full Text] [Related]
20. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis.
de Visser MC; Rosendaal FR; Bertina RM
Blood; 1999 Feb; 93(4):1271-6. PubMed ID: 9949170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
